Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
A Randomized Phase III Study Comparing Concomitant Docetaxel Plus Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients
Sponsor: Central European Cooperative Oncology Group
A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Central European Cooperative Oncology Group and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central European Cooperative Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beirut, Lebanon , Bratislava, Slovakia , Brno, Czechia , Ceske, Czechia , Haifa, Israel , Hradec Králové, Czechia , Krakow, Poland , Plovdiv, Bulgaria , Prague, Czechia , Sofia, Bulgaria and 5 more locations